NeuroPace, Inc. has announced the presentation of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS clinical trial at the American Epilepsy Society $(AES)$ meeting. The NAUTILUS trial is evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy $(IGE)$ with generalized tonic-clonic (GTC) seizures. The RNS System is a brain-responsive device designed to deliver real-time, personalized treatment at the seizure source. Further details regarding the trial can be found on the NeuroPace website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208932472) on December 08, 2025, and is solely responsible for the information contained therein.